Full Press Release Details
IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform.
IDYA
IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform
Key Takeaway: IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma